Early Feasibility Study (EFS) of the Cardiac Implants Percutaneous Ring Annuloplasty System for the Treatment of Functional Tricuspid Regurgitation
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Tricuspid Regurgitation Functional
- Sponsor
- Cardiac Implants LLC
- Enrollment
- 15
- Locations
- 2
- Primary Endpoint
- Freedom from device or procedure-related mortality
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
An early feasibility study to evaluate the safety and performance of 1) the transcatheter delivery and implantation of the Cardiac Implants (CI) annuloplasty ring and 2) the adjustment of the ring approximately 90 days following implantation in patients suffering from ≥ moderate functional tricuspid regurgitation (FTR).
Detailed Description
An early feasibility, multi-center, prospective, single-arm, non-randomized study to assess the safety and performance of the CI Percutaneous Ring Annuloplasty System in patients suffering from ≥ moderate functional tricuspid regurgitation (FTR). Additional outcomes include short and long-term changes in echocardiographic, functional, and quality of life parameters post-adjustment. The CI Ring Annuloplasty System is a percutaneous transcatheter repair device delivered by right heart catheterization through the right internal jugular vein. The System is designed to perform annuloplasty using a Ring Delivery System (RDS) to place a complete, flexible ring over the tricuspid annulus on the atrial side of the valve. Fluoroscopy and transesophageal echocardiography are used to guide and monitor the ring placement procedure. After implantation, the ring becomes embedded within the fibrous tissue of the tricuspid annulus. Approximately 3 months following implantation, the ring is manually adjusted under echocardiographic and fluoroscopic imaging using an Adjustment Tool (AT) until desired reduction of the tricuspid annulus dimension is achieved. Following adjustment, the AT releases a fastener, securing the ring once optimal annular reduction is achieved.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Moderate to severe functional tricuspid regurgitation (TR) defined by ASE guidelines and the European Association of Echocardiography guidelines.
- •Tricuspid valve annular diameter ≥ 40mm or \> 21 mm/m2 as measured by baseline TTE in a 4-chamber view within 90 days prior to index implant procedure.
- •Age ≥ 18 years old at the time of enrollment.
- •New York Heart Associate Classification ≥ II.
- •Symptoms of right heart failure despite optimized medical therapy.
- •Multidisciplinary heart team (minimum of four physicians, including imaging, Structural Heart Disease Interventionalist, Heart Failure Cardiologist, and Cardiac Surgeon) agree that percutaneous tricuspid annuloplasty is a reasonable treatment.
- •Left Ventricular Ejection Fraction (LVEF) ≥ 30% within 90 days prior to index implant procedure
- •The subject has suitable anatomy for investigational device implantation as per imaging requirements.
- •The subject has read and signed the informed consent prior to study related procedures.
- •The subject is willing and able to comply with all required follow-up evaluations and assessments.
Exclusion Criteria
- •Acute decompensated heart failure requiring hospital admission with 4 weeks of enrollment.
- •Severe RV dysfunction as assessed by echocardiography.
- •Primary (organic) tricuspid pathology (e.g. rheumatic, congenital, infective, etc.).
- •Currently participating in another investigational drug or device study.
- •Systolic pulmonary arterial pressure (sPAP) \> 70 mmHg as measured by Transthoracic Echocardiography (TTE).
- •Subject requiring another cardiac procedure in the framework of the index procedure; subject requiring a percutaneous procedure within 30 days before or after the procedure or a cardiac surgical procedure within 3 months before or after the procedure.
- •Tricuspid valve stenosis.
- •Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation more than moderate.
- •Intra-cardiac thrombus, mass or vegetation requiring active treatment.
- •Prior tricuspid repair or tricuspid replacement.
Outcomes
Primary Outcomes
Freedom from device or procedure-related mortality
Time Frame: 30 days post-adjustment
Freedom from mortality determined to be primarily caused by the device or procedure in the primary endpoint cohort. Events adjudicated by a Clinical Events Committee (CEC).
Secondary Outcomes
- Safety: Incidence of device or procedure-related major adverse events (MAE)(30, 60, and 90 days post-implant; 30 days, 3 months, 6 months, 12 months, and 2-5 years (annually) post-adjustment)
- Technical: Proportion of successful deployment and positioning of the ring implant.(30 days post-implant and 30 days post-adjustment)
- Technical: Freedom from emergency surgery or reintervention(30 days post-implant and 30 days post-adjustment)
- Technical: Rate of Successful Implants(30 days post-implant)
- Technical: Number of device stakes embedded in tissue(30 days post-implant, 30 days post-adjustment, and 1 year post-adjustment)
- Mechanistic: Changes in TR Severity(30 and 90 days post-implant; and 30, 90, 180, and 1-2 years (annually) post-adjustment)
- Mechanistic: Echocardiographic changes: Changes Tricuspid Valve (TV) Annular Diameter(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Quantitive EROA(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Right Atrium (RA) Dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Tricuspid Annular Plane Systolic Excursion (TAPSE)(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Technical: Proportion of successful access, delivery, and retrieval device delivery system(30 days post-implant and 30 days post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in TV Area(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Vena Contracta (VC) dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Functional: Changes in NYHA Classification(1 year post-adjustment)
- Functional: Changes in Quality of Life Scores and Sub-Domains(1 year post-adjustment)
- Technical: Proportion of Successful Procedures(30 days post-implant and 30 days post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in TV Regurgitant Volume(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Proximal isovelocity surface area (PISA) effective regurgitant orifice area (EROA)(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Right Ventricle (RV) Dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Left Atrium (LA) Dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Inferior Vena Cava (IVC) Dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Mechanistic: Echocardiographic changes: Changes in Left Ventricle (LV) Dimensions(30 days, 90 days, 180 days, 1 year, and 2 years post-adjustment)
- Functional: Changes in Distance Walked for Exercise Tolerance(1 year post-adjustment)